 |
|
MI Risks Linked to Rosiglitazone
Tracy Hampton, PhD
JAMA. 2007;298:1149-1151.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Recent reports and discussions examining potential cardiovascular adverse effects of the diabetes drug rosiglitazone have left many clinicians uncertain about whether to prescribe the drug for their patients. A meta-analysis suggested that the drug was associated with a significantly increased risk of myocardial infarction among patients with type 2 diabetes (Nissen SE and Wolski K. N Engl J Med. 2007;356[24]:2457-2471), while findings from an unplanned interim analysis of data from an ongoing clinical trial were inconclusive (Home PD et al. N Engl J Med. doi:10.1056/NEJMoa073394 [published online ahead of issue June 5, 2007]).
The issue was discussed at the 67th Scientific Sessions of the American Diabetes Association in June as well as during an advisory panel of the US Food and Drug Administration (FDA) held in Gaithersburg, Md, at the end of July. After intense scrutiny of rosiglitazone studies, experts concluded that the diabetes drug . . . [Full Text of this Article] RECORD TRIAL
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes
Lehmann and Lohray
J Clin Pharmacol 2008;48:999-1002.
FULL TEXT
|
